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Abbreviation list: BAFF=B-cell activating factor; BALT=bronchus-associated lymphoid tissue; 
COPD=chronic obstructive pulmonary disease; Ig=immunoglobulin; IL=interleukin; LF=lymphoid 
follicles; mAbs=monoclonal antibodies; Th=T-helper;  
 
Abstract  
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality 
worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized 
countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the 
age of 80 years. COPD is characterized by an abnormal immune response in the lower airways and 
its progression is associated with infiltration of the lung by innate and adaptive inflammatory 
immune cells that form lymphoid follicles. There is growing evidence that both cellular- and 
antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In 
particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and to cause the 
characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary 
emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in 
stable COPD patients has been identified, no cause-and-effect relationship between autoimmunity 
and the mechanisms of COPD has been firmly established in man. As such the potential 
contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being 
investigated and represents an area of active research. Many drugs targeting autoimmune responses 
are already available and the results of controlled clinical trials are awaited with great interest. The 
potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes 
or progression of stable COPD is promising. 
 
Immune system in the normal adult human lung  
Normal adult human lungs contain ∼30x109 lymphocytes representing 7% of the total number of 
lymphocytes of the body. The lungs represents, therefore, a major lymphoid organ with a complex 
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functional organization that is only partially understood.1,2 
There is a prevalence of CD3+ T-cells, that,  together with the gut, comprises ∼14-15% of  the total 
number of CD4+ and CD8+ cells of the body.2,3 The CD4+/CD8+ lung ratio is ∼1, with a high 
prevalence of CD103+/integrinβ7+/CCR5+ memory T-cells but with only a minority of 
CD3+TCRγδ+ (γδT) cells.3,4 The latter can influence B cell differentiation, control levels of 
circulating immunoglobulins and affect autoantibody production.5 Both CD27+/CCR5+ and CD27–
CCR5+ resident memory cells (Trms) are found primarily in the lung whilst CD69+CD103– effector 
memory (Tem) cells are also abundant in the lung.4 T-helper (Th)-cells cannot be easily separated 
into distinct lineages in human tissues, as often secrete multiple Th-cell-associated cytokines. 
However, Th1 [interferon (IFN)-γ+]-cells are found at the highest frequencies in the normal human 
lung.4 It is noteworthy that only a small fraction (<6%) of these Th-cells are interleukin(IL)-4+ 
(Th2), IL-9+ (Th9), IL-10+ (Th10), IL-17A+ (Th17) or IL-22 (Th22) whereas around 50% of the Th-
cells are granulocyte-macrophage colony-stimulating factor (GM-CSF)+ that may protect against 
autoimmune diseases.4,6 Th17 cells may play a pathogenic role in autoimmune diseases through the 
actions of IL-17A, IL-21 and IL-22 whereas C 4+/CD25+ forkhead box P3 (FOXP3)+ T-regulatory 
(Treg) cells are critical for sustaining immune tolerance through IL-10 and transforming growth 
factor-β production.7 
CD19+ B-cells (CCR6+CCR7+CXCR5+) represent less of 5% of all lymphocytes whereas natural 
killer (NK, CD3-/CD56+) and NKT (CD3+/CD56+) cells contribute ∼25% of all lymphocytes.3,4  
Constitutive bronchus-associated lymphoid tissue (BALT) is not usually present in healthy human 
adults whereas inducible BALT (iBALT), an ectopic tertiary lymphoid structure composed of 
highly organized T- and B-cell zones with proliferating lymphocytes that forms in the lung in 
response to inflammation, including autoimmunity, can be found throughout the human lung. Both 
BALT and iBALT acquire antigens from the airways and initiate local immune responses 
maintaining memory cells in the lung.8 
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Autoimmune responses in the pathogenesis of stable COPD  
Chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality 
worldwide, is caused by complex interactions between environmental factors (particularly cigarette 
smoking) and genetic factors. Long term cigarette smoking causes >90% of COPD in Westernized 
countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the 
age of 80 years.9 
The progressive chronic airflow limitation in COPD is due to two major pathological processes: 
remodelling and narrowing of small airways and destruction of the lung parenchyma with 
consequent loss of the alveolar attachments of these airways due to pulmonary emphysema. This 
results in diminished lung recoil, higher resistance to flow, and closure of small airways at higher 
lung volumes during expiration, with consequent air trapping in the lung. This leads to the 
characteristic hyperinflation of the lungs, which gives rise to the sensation of dyspnoea and 
decrease exercise tolerance. Both the small-airway remodelling and narrowing and the pulmonary 
emphysema are likely to be the results of chronic lung inflammation.10  
COPD is characterized by an abnormal immune response in the lower airways with disease 
progression associated with infiltration of innate and adaptive inflammatory immune cells that form 
lymphoid follicles (LF). For this reason the inflammatory response present in the lower airways of 
stable COPD is considered an amplification of the inflammatory response to smoking that is seen in 
smokers with normal lung function.9  
LF are rarely observed in the small airways of non-smokers, but they are present in the small 
airways of approximately 5% of smokers with normal lung function, as well as in smokers with 
mild to moderate COPD. Their prevalence increases sharply to 25–30% in severe and very severe 
COPD for unclear reasons. The LF in the small airways of COPD patients are large aggregates of 
B-cells, with interspersed CD21+ and CD35+ follicular dendritic cells surrounded by lower numbers 
of CD4+ (80–90%) and few CD8+ T-cells.9,10 
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The major T and B cell subsets involved in the pathogenesis of stable COPD (cell type and related 
functions) are summarized in table 1. 9,10 
There is growing evidence that autoimmunity has a role in the pathogenesis of stable COPD. 
Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD 
has been identified (Fig 1), no cause-and-effect relationship between autoimmunity and COPD 
mechanisms has been established 11 and represents an area of intense active research.  
We have not discussed any data on COPD exacerbations because of the absence of studies showing 
a role of autoimmunity in the pathogenesis of COPD exacerbations. 
 
B cells and autoantibody-mediated lung damage in the pathogenesis of stable COPD 
More of half century after the first demonstration of the presence of serum antibodies reactive 
against human lung tissues in patients with “idiopathic obstructive emphysema”12 the role of B-cells 
and autoantibodies in the pathogenesis of stable COPD is still unknown. Although pulmonary 
emphysema usually only appears with increasing COPD severity, it can also occur in patients 
without airflow obstruction.9,10 It is interesting to note that most of the evidence supporting the 
presence of an autoantibody-mediated autoimmune response in stable COPD patients has been 
gathered from studies of the more advanced grades of the diseases that are often associated to the 
presence of significant pulmonary emphysema. This suggests that autoantibodies may contribute to 
the pathogenesis of pulmonary emphysema. 
B-cells localized in the peripheral lung of stable COPD are mainly immunoglobulin (Ig)M-bearing 
and IgD-negative, which suggests a degree of activation. Moreover, a predominant part of these 
cells is CD27+, a marker for memory B-cells. In one study, where LF were isolated from the small 
airways of stable COPD patients, oligoclonal B-cells were find suggesting that they play a role in 
local antigen specific autoimmune responses.9 B-cells organized in iBALT structures and 
macrophages accumulate in the lungs and contribute to cigarette smoke (CS)-induced pulmonary 
emphysema, and B cell-deficient mice is significantly protected against CS-induced emphysema.13  
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Natural (because they are produced at birth in the absence of exposure to foreign antigens) IgM 
autoantibodies (IgM-NAA) are present in the serum of the normal subjects  and show poly-
reactivity with low binding affinity, but with high avidity. This response provides time for the 
adaptive immune system to mount a highly specific immune response to foreign antigens lessening 
the necessity to produce highly specific IgG auto-antibodies, with the potential of causing 
autoimmune disease owing to their high-affinity binding.14 
However, serum and/or lung IgM, IgG and less frequently IgA autoantibodies are often (but not 
always) found in both smokers with normal lung function and stable COPD patients. These are not 
disease-specific being directed against rheumatoid factor (RF), nuclei (ANA), lung, lower airways 
epithelium (including their cytokeratin 18 and 19), endothelium, anti-cyclic citrullinated peptide 
(anti-CCP) and/or extracellular matrix components (such as elastin, collagen I, and V, decorin) and 
many other epitopes (for example mutated citrullinated vimentin or CD80). In most cases their 
presence significantly correlates with smoking rather than with the degree of airflow limitation.9,15-
20 and references cited therein
 
Carbonyl-modified proteins, arising due to oxidative/nitrosative stress (Fig 2), promote serum auto-
antibody production in stable COPD.21 The serum antibody titer against carbonyl-modified self-
proteins significantly increases in patients with severe stable COPD compared with control subjects. 
Auto-antibody levels correlate inversely with disease severity and are predominantly IgG1 in type. 
Deposition of activated complement in the vessels of peripheral COPD lung as well as 
autoantibodies against endothelial cells is also seen. Ozone-exposed mice, a model of COPD, show 
increased antibody titers to carbonyl-modified protein, as well as activated antigen-presenting cells 
in lung tissue and splenocytes sensitized to carbonyl-modified protein.21 This confirmed previous 
observations showing the presence of serum and lung immune complexes in stable COPD 
patients.17,22 
B-cell activating factor [BAFF, also termed B-lymphocyte stimulator (BLyS)] belongs to the tumor 
necrosis factor (TNF) family and is responsible for B-cell survival and maturation and its 
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overexpression is associated with autoimmune diseases.23 BAFF is overexpressed  
in bronchiolar LF and in the small airways from stable COPD patients compared to control non-
smokers but not in control smokers with normal lung function. BAFF overexpression creates a self-
perpetuating loop contributing to COPD progression by promoting pulmonary B-cell survival and 
LF expansion.24 Antagonizing BAFF in cigarette-smoke (CS)-exposed mice attenuates pulmonary 
inflammation and alveolar destruction.25 
IL-6 (originally identified as a B-cell differentiation factor) is a multifunctional cytokine that may 
contribute to the pathogenesis of the autoimmune response observed in the lungs of severe stable 
COPD patients.9,26 
IL-17A in the peripheral lung of patients with advanced COPD may contribute to disease 
progression and the development of lymphoid follicles via activation of CXCL12.27 A major source 
of IL-17A is the CD4+ TH17 cell, which also releases IL-21 and IL-22, expresses the transcription 
factor retinoic acid–related orphan receptor γt (RORγt and called RORC2 in humans). Although 
Th17 cells are typically considered to be the principal source of IL-17, CD8+ cells have also been 
shown to make this cytokine, and are termed ‘Tc17’. In addition, several innate-acting lymphocytes 
such as IL-17+ type 3 innate lymphoid cells (ILC3s) which lack an antigen receptor, γδT cells, some 
NKT cells, and TCRβ+natural Th17 cells produce IL-17A. Collectively, these IL-17-producing cells 
are often termed type 17.28  
In animal models microbiota may promotes chronic pulmonary inflammation by enhancing IL-17A 
expression and the subsequent synthesis of autoantibodies and an imbalance of the microbiome has 
been recently reported in bronchial biopsies of stable COPD patients. 29,30 
Cell-mediated autoimmune lung damage in the pathogenesis of stable COPD 
The first evidence to the hypothesis that stable COPD may be caused by T‐cell inflammation and 
autoimmunity derived from the presence of an increased number of activated signal transducer and 
activator of transcription (STAT)-4 and IFN‐γ CD4+ T‐cells in bronchial biopsies and BAL that 
correlate with decreasing lung function.31 
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This indicates that activated T‐cells, through Th1 cytokines, along with CD8+ T‐cells and innate 
immune cells recruited by Th1 cytokines, are damaging the lung.32 Subsequently, severe 
emphysema has been associated with lung oligoclonal CD4+ and CD8+ T cells33,34 and the presence 
of ADCC against bronchial epithelium in stable COPD.17 In addition, in animal models chronic CS 
exposure generates pathogenic T-cells inducing a COPD-like disease.35 
Cytotoxic pro-inflammatory CD8+ T-cells and CD8+ NKT-like cells are increased in the peripheral 
blood and airways of COPD patients, but only in the lungs of smokers with normal lung function. In 
COPD, these senescent cells express increased levels of the cytotoxic mediators, perforin and 
granzyme B, and the pro-inflammatory cytokines IFN-γ and TNF-α and have increased cytotoxicity 
toward lung epithelial cells.36 
Production of these pro-inflammatory mediators by lung-resident CD8+ T-cells may contribute to 
the pathogenesis of stable COPD.9,26 In animal models of emphysema there is persistence of lung 
oligoclonal CD8+ T-cells upon smoking cessation.37 This may lead to chronic activation of 
macrophage subtypes that preclude proper healing of the lung and, thereby, contributing to 
pulmonary emphysema.38 
 
Diagnostic implications 
Autoantibodies may play a pathogenic role in the pathogenesis of COPD progression and in the 
pathogenesis of autoimmune emphysema (Fig 3). Furthermore, serum autoantibodies may act as 
biomarkers to predict clinical phenotypes or progression of stable COPD. A United States of 
America patent application (20160097778) has been filled on a method for determining COPD 
progression (and thus prognosis) and/or in selecting a personalised treatment, based on measuring 
serum autoantibody response to carbonylated vimentin (an intracellular intermediate filament 
expressed in mesenchymal cells) (http://www.freepatentsonline.com/y2016/0097778.html). 
 
Therapeutic implications 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CHEST-17-1943R1 unmarked copy 
 9 
In contrast to asthma, glucocorticoid treatment of stable COPD is rather ineffective in reducing 
airway inflammation and lung function decline.39 However, long term withdrawal of inhaled 
glucocorticoids in stable COPD patients results in a significant rise in the number of CD3+, CD4+ 
and CD8+ T-cells in the bronchial mucosa.40 Inhaled glucocorticoids may reduce the adaptive 
immune response in stable COPD and may be more effective in patients with an increased B-cell 
response indicated by high autoantibody titer.41 Unfortunately, this may also account for the small 
increased risk of pneumonias observed in stable COPD patients on high dose inhaled 
glucocorticoids.26,39  
Macrolide antibiotics, such as azithromycin and erythromycin, have immunomodulatory/anti-
inflammatory  effects.42 Long term treatment with these drugs reduce the frequency of 
exacerbations in patients with moderate to very severe COPD and a history of frequent 
exacerbations.43 However, this is associated with an increased risk of adverse events and emergence 
of macrolide-resistance. Therefore, non-antibiotic macrolides with immunomodulatory/anti-
inflammatory effects are under preclinical development.42,44 
In addition there are many potential anti–B-cell–directed therapies that are in clinical use for the 
treatment of autoimmune diseases which have potential for the treatment of stable COPD patients. 
B-cell depletion by anti-CD20 monoclonal antibodies (mAbs) rituximab, ocrelizumab and 
ofatumumab have efficacy in multiple sclerosis.45 CD20 regulates cell cycle progression in B-cells 
and in mice loss of CD20 functions leads to a 20-30% reduction in B-cell numbers with low serum 
IgG and normal IgM levels.46 Epratuzumab is a B-cell-directed non-depleting anti-CD22 mAb, 
which results in reduced B-cell receptor (BCR) complex signalling by intensifying the normal 
inhibitory role of CD22 on the BCR and diminishing B-cell activation, that is in phase 3 clinical 
trials in patients with systemic lupus erythematosus (SLE).47 BAFF plays a central role in the 
induction and maintenance of CS-induced pulmonary autoantibodies suggesting a therapeutic 
potential for BAFF blockade in limiting autoimmune processes associated with smoking.48 
Belimumab, a mAb anti-BAFF (reducing B-cell differentiation and survival) is the first drug to be 
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approved specifically for the treatment of SLE in more than 50 years.49  
Anti-IL-6 blocking mAbs (including siltuximab and tocilizumab), although used in clinical trials of 
rheumatoid arthritis and cancers have not been tested on COPD patients.26,39 
Secukinumab and ixekizumab are mAbs that selectively binds and neutralizes IL-17A blocking its 
binding to the IL-17 receptor (IL-17R) and have been approved for the treatment of psoriasis.50 
However, CNTO 6785, another anti-IL-17A mAb, was ineffective in a phase 2 randomised 
controlled trial (RCT) of stable COPD.51 Brodalumab, a mAb blocking IL-17Rα, has been tested in 
patients with severe asthma. 26,39 
IL-23, a key regulator of Th17 cells, can be inhibited by specific mAbs (guselkumab and 
tildrakizumab) or ustekinumab, which blocks the shared p40 component of IL-12 and IL-23. These 
are all effective in the treatment of psoriasis.26,39 Low molecular weight, cell-permeable RORC2 
antagonists and novel RORC2-independent modulators of IL-17A have been identified.52 
In addition, statin treatment reverses the IL-17A/IL-10 imbalance in the airways of stable COPD 
patients but, unfortunately, statins are clinically ineffective in the long-term treatment of these 
patients.26 
Anti-CD3 (expressed on ∼90% of lung T-cells) mAbs effectively treat autoimmune disease in 
animal models and show promise in clinical trials. The development of tolerance by anti-CD3 
mAbs is related to the induction of Tregs.53 
It is unlikely that mouse models of COPD will be more predictive than those reported to date. This 
demands the testing of novel therapies in RCTs in patients with stable COPD to demonstrate 
efficacy on COPD exacerbations and disease progression. Close monitoring of infectious and non-
infectious adverse events is mandatory. In fact, blocking immune responses might be associated 
with reduced immunity to infections.  
 
Conclusions 
There is growing evidence that ultimately autoimmunity, like so many other facets of 
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pathophysiology linked with COPD, is likely to play a more central role in the progression of the 
disease in certain subgroups of COPD patients rather than a unifying central across all COPD. Both 
antibody and cell-mediated responses appear to be involved in autoimmune responses and in the 
development of lung damage. In particular, carbonyl-modified proteins may drive autoimmune 
mechanisms in COPD causing the characteristic small airways abnormalities and pulmonary 
emphysema. Drugs that target this autoimmune response are available and the results of controlled 
clinical trials are awaited with great interest. The potential for measuring specific serum 
autoantibodies as biomarkers to predict clinical phenotypes, progression of stable COPD or drug 
response is promising. 
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Table 1. Major T and B cell subsets involved in the pathogenesis of stable COPD. 
 
Cell Type Function Expression Comments 
B cell Humoral immunity □ Identified in the secondary 
lymphoid follicles of the COPD 
lung as mainly IgM+, IgD- 
CD57+ B cel Memory B cells □ Observed mainly in the lower 
airways GOLD 3 and 4 grades 
CD3+ T cells Cell mediated 
immunity 
□ Includes both CD4+ and CD8+ T 
cells.  Numbers in the lower 
airways are significantly elevated 
in GOLD 3 and 4 compared to 
GOLD 1 and 2 grades. 
CD8+ T cell Cytotoxic cellular 
immunity 
□□ Elevated in blood and lower 
airways.  These cells are highly 
activated expressing perforin and 
granzyme B. 
CD4+ T cell Provide help adaptive 
immune response 
□ Increased mainly in blood. 
CD8+ - IFNγ/Il-4 ratio Defines Th1 (more 
IFNγ) versus Th2 
(more IL-4) immune 
response 
□ 
 
Their ratio in the lower airways 
compartments can define whether 
the immune response is directed 
towards intracellular pathogens 
(Th1) as opposed to extracellular 
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pathogens (Th2). 
CD8/CD4 ratio Indicative of abnormal 
immune response 
□ Most significant increase in the 
lower airways of COPD in GOLD 
3 and 4 grades where ratio = 4 (a 
normal ratio = 0.5).  This 
increased CD8/CD4 ratio is 
associated with the severity of 
airflow limitation in COPD. 
Th17 cells B cell maturation, also 
facilitates neutrophils 
and macrophage 
recruitment for 
mucosal immunity 
□□ High levels of IL-17 are strongly 
linked to development of 
autoimmune disorders.  In the 
lower airways of stable COPD, 
only 5% of IL-17 is from Th17 
cells, the other 95% of IL-17 is 
from CD31+ endothelial cells. 
CD25+ Treg cells Maintains the 
immunological 
tolerance by 
suppressing activated 
self-reactive T cells 
□□ Decreased in the lower airways of 
COPD.  All the Treg cell express 
the master transcription factor 
regulator FoxP3, its expression in 
the lower airways is inversely 
correlated to airflow limitation. 
 
Obtained with the data from references 9, 10.  
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Figure legends 
Figure 1. Autoimmunity develops in chronic obstructive pulmonary disease (COPD) when 
environmental triggers (usually cigarette smoking) transform the production of benign 
autoantibodies to pathogenic antibodies in susceptible subjects. With the progression of the 
autoimmune response there is the deposition of immune complexes within the lower airways and 
the local activation of cell mediated autoimmune damage which causes lower airway chronic 
inflammation. This is followed by a slowly progressive remodelling of the lower airways (chronic 
bronchiolitis and pulmonary emphysema) and by the clinical diagnosis of the disease (COPD) 
(slightly adapted from reference 9 under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/) 
Figure 2. Oxidative (ROS) and nitrosative (RNS) stress from environmental (for example cigarette 
smoking, air pollution,  indoor biomass smoke) and endogenous sources [for example 
myeloperoxidase (MPO), mitochondrial respiration, nicotinamide adenine dinucleotide phosphate 
reduced oxidase complex, xanthine oxidase] may causes direct tissue damage through lipids, 
proteins, carbohydrates and deoxyribonucleic acid (DNA) damage. However may also causes the 
formation of carbonyl stress that through post-translational, non-enzymatic, modifications on 
proteins can alter their function and result in the formation neo-autoantigens triggering an 
autoimmune response in the lower airways of smokers that in susceptible subjects is associated with 
a slowly progressive damage of the lower airways and development of chronic obstructive 
pulmonary disease (COPD). ROS =reactive oxygen species. RNS=reactive nitrogen species. 
 
Figure 3. Diagnostic and therapeutic implications of the pathogenic role of autoimmunity in stable 
COPD patients. 
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